Illustrative image – not actual.Mylab Discovery Solutions has forayed into the vaccine and therapeutics segment with a strategic tie-up with Shilpa Biologicals.
In addition to Covid-19 vaccine manufacturing, the parties plan to expand the product portfolio in other areas like biosimilars, other vaccines & diagnostics.
Mylab plans to develop world-class diagnostics, vaccines and therapeutics to augment its presence in the healthcare market.
The company will leverage the technical expertise of Shilpa Biologicals in development and manufacture of biopharmaceuticals through its world class facility at Dharwad spread across 11 acre in Karnataka.
The first vaccine project under this long-term partnership is currently under final evaluation phase and the manufacturing is expected to start by March 2022.
In addition to Covid-19 vaccine manufacturing, the parties plan to expand the product portfolio in other areas like biosimilars, other vaccines & diagnostics.
Mylab plans to develop world-class diagnostics, vaccines and therapeutics to augment its presence in the healthcare market.
The company will leverage the technical expertise of Shilpa Biologicals in development and manufacture of biopharmaceuticals through its world class facility at Dharwad spread across 11 acre in Karnataka.
The first vaccine project under this long-term partnership is currently under final evaluation phase and the manufacturing is expected to start by March 2022.
